CNCE - Concert's CTP-543 helps hair regrowth in alopecia areata patients meets trial's main goal

Concert Pharmaceuticals (NASDAQ:CNCE) said a phase 3 trial of its oral drug CTP-543 met the main goal of scalp hair regrowth at both doses in patients with moderate to severe alopecia areata, an autoimmune disorder causing scalp hair loss. The late-stage study, called THRIVE-AA1, included 706 adult patients aged 18 years to 65 years with moderate to severe alopecia areata at sites in the U.S., Canada and Europe. The trial evaluated the regrowth of scalp hair after 24 weeks of therapy using the SALT score ( a score of 100 represents total scalp hair loss, while 0 represents no scalp hair loss). The company said a statistically significant proportion of patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 experienced greater scalp regrowth compared to placebo. The main goal was the percentage of patients achieving a SALT score ? 20 at 24 weeks. Concert added that

For further details see:

Concert's CTP-543 helps hair regrowth in alopecia areata patients, meets trial's main goal